<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37525032</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1423</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>An Updated Evolutionary and Structural Study of TBK1 Reveals Highly Conserved Motifs as Potential Pharmacological Targets in Neurodegenerative Diseases.</ArticleTitle><Pagination><StartPage>41</StartPage><EndPage>57</EndPage><MedlinePgn>41-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-031-31978-5_5</ELocationID><Abstract><AbstractText>TANK-binding kinase 1 protein (TBK1) is a kinase that belongs to the I&#x3ba;B (IKK) family. TBK1, also known as T2K, FTDALS4, NAK, IIAE8, and NF-&#x3ba;B, is responsible for the phosphorylation of the amino acid residues, serine and threonine. This enzyme is involved in various key biological processes, including interferon activation and production, homeostasis, cell growth, autophagy, insulin production, and the regulation of TNF-&#x3b1;, IFN-&#x3b2;, and IL-6. Mutations in the TBK1 gene alter the protein's normal function and may lead to an array of pathological conditions, including disorders of the central nervous system. The present study sought to elucidate the role of the TBK1 protein in amyotrophic lateral sclerosis (ALS), a human neurodegenerative disorder. A broad evolutionary and phylogenetic analysis of TBK1 was performed across numerous organisms to distinguish conserved regions important for the protein's function. Subsequently, mutations and SNPs were explored, and their potential effect on the enzyme's function was investigated. These analytical steps, in combination with the study of the secondary, tertiary, and quaternary structure of TBK1, enabled the identification of conserved motifs, which can function as novel pharmacological targets and inform therapeutic strategies for amyotrophic lateral sclerosis.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papageorgiou</LastName><ForeName>Louis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangana</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papakonstantinou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diakou</LastName><ForeName>Io</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierouli</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragoumani</LastName><ForeName>Konstantina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacopoulou</LastName><ForeName>Flora</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University Research Institute of Maternal and Child Health &amp; Precision Medicine, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrousos</LastName><ForeName>George P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>University Research Institute of Maternal and Child Health &amp; Precision Medicine, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Exarchos</LastName><ForeName>Themis P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Bioinformatics &amp; Human Electrophysiology Laboratory, Department of Informatics, Ionian University, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlamos</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bioinformatics &amp; Human Electrophysiology Laboratory, Department of Informatics, Ionian University, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eliopoulos</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlachakis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, Greece. dimvl@aua.gr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Research Institute of Maternal and Child Health &amp; Precision Medicine, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece. dimvl@aua.gr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. dimvl@aua.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C403191">TBK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Conserved motifs</Keyword><Keyword MajorTopicYN="N">Evolutionary analysis</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">Pharmacological targets</Keyword><Keyword MajorTopicYN="N">Structural analysis</Keyword><Keyword MajorTopicYN="N">TBK1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37525032</ArticleId><ArticleId IdType="doi">10.1007/978-3-031-31978-5_5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masrori P and Van Damme P: Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27: 1918&#x2013;1929, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId><ArticleId IdType="pmc">7540334</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R and Mariotti R: ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles. Front Cell Neurosci 11: 80, 2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00080</ArticleId><ArticleId IdType="pubmed">28377696</ArticleId><ArticleId IdType="pmc">5359305</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, et al.: A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 6: 171, 2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId><ArticleId IdType="pmc">4653353</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD and Akkari PA: ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci 13: 1310&#x2013;1310, 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId><ArticleId IdType="pmc">6909825</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Horton DK and Mitsumoto H: Potential Environmental Factors in Amyotrophic Lateral Sclerosis. Neurol Clin 33: 877&#x2013;888, 2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.009</ArticleId><ArticleId IdType="pubmed">26515627</ArticleId><ArticleId IdType="pmc">4646848</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM and Lacomis D: Chapter 13 &#x2013; The epidemiology of amyotrophic lateral sclerosis. In: Handbook of Clinical Neurology. Vol 138. Aminoff MJ, Boller F and Swaab DF (eds). Elsevier, pp 225&#x2013;238, 2016.</Citation></Reference><Reference><Citation>Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Al Khleifat A, Smith BN, Topp S, Morrison KE, et al.: Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry 90: 268&#x2013;271, 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319089</ArticleId><ArticleId IdType="pubmed">30270202</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA and Henderson RD: Effects of gender in amyotrophic lateral sclerosis. Gender Medicine 7: 557&#x2013;570, 2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R and Isaacs AM: C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14: 544&#x2013;558, 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId><ArticleId IdType="pmc">6417666</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F and Polymenidou M: Advances and challenges in understanding the multifaceted pathogenesis of amyotrophic lateral sclerosis. Swiss Med Wkly 145: w14054, 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">25635517</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew AS, Bradley WG, Peipert D, Butt T, Amoako K, Pioro EP, Tandan R, Novak J, Quick A, et al.: Risk factors for amyotrophic lateral sclerosis: A regional United States case-control study. Muscle Nerve 63: 52&#x2013;59, 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27085</ArticleId><ArticleId IdType="pubmed">33006184</ArticleId></ArticleIdList></Reference><Reference><Citation>Delzor A, Couratier P, Boumediene F, Nicol M, Druet-Cabanac M, Paraf F, Mejean A, Ploux O, Leleu JP, et al.: Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. BMJ Open 4: e005528, 2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2014-005528</ArticleId><ArticleId IdType="pubmed">25180055</ArticleId><ArticleId IdType="pmc">4156816</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Beard JD, Umbach DM, Bellocco R, Keller J, Peters TL, Allen KD, Ye W, Sandler DP, et al.: Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans. Am J Epidemiol 185: 362&#x2013;371, 2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kww140</ArticleId><ArticleId IdType="pubmed">28158443</ArticleId><ArticleId IdType="pmc">5860019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas P, Ramirez AI, Fernandez-Albarral JA, Lopez-Cuenca I, Salobrar-Garcia E, Cadena M, Elvira-Hurtado L, Salazar JJ, de Hoz R, et al.: Amyotrophic Lateral Sclerosis: A Neurodegenerative Motor Neuron Disease With Ocular Involvement. Front Neurosci 14: 566858, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.566858</ArticleId><ArticleId IdType="pubmed">33071739</ArticleId><ArticleId IdType="pmc">7544921</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M, Tortorice K, Zacher J, Dong D, Hur K, Zhang R, Good CB, Glassman PA and Cunningham FE: Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System. JAMA Netw Open 3: e2014645, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.14645</ArticleId><ArticleId IdType="pubmed">33017028</ArticleId><ArticleId IdType="pmc">7536587</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G and Al-Chalabi A: Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17: 416&#x2013;422, 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId><ArticleId IdType="pmc">5899963</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves A, B&#xfc;rckst&#xfc;mmer T, Dixit E, Scheicher R, G&#xf3;rna MW, Karayel E, Sugar C, Stukalov A, Berg T, et al.: Functional Dissection of the TBK1 Molecular Network. PLOS ONE 6: e23971, 2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023971</ArticleId><ArticleId IdType="pubmed">21931631</ArticleId><ArticleId IdType="pmc">3169550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yum S, Li M, Fang Y and Chen ZJ: TBK1 recruitment to STING activates both IRF3 and NF-&#x3ba;B that mediate immune defense against tumors and viral infections. Proceedings of the National Academy of Sciences 118: e2100225118, 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2100225118</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes JA, Davies MC and Collins MO: TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain 10: 5&#x2013;5, 2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId><ArticleId IdType="pmc">5288885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, Tas L, Huizinga R, Dalm V, van Hagen PM, Groot N, Kamphuis S, et al.: TBK1: A key regulator and potential treatment target for interferon positive Sjogren&#x2019;s syndrome, systemic lupus erythematosus and systemic sclerosis. J Autoimmun 91: 97&#x2013;102, 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.02.001</ArticleId><ArticleId IdType="pubmed">29673738</ArticleId></ArticleIdList></Reference><Reference><Citation>Abreha MH, Ojelade S, Dammer EB, McEachin ZT, Duong DM, Gearing M, Bassell GJ, Lah JJ, Levey AI, et al.: TBK1 interacts with tau and enhances neurodegeneration in tauopathy. Journal of Biological Chemistry 296: 2021.</Citation></Reference><Reference><Citation>Le Ber I, De Septenville A, Millecamps S, Camuzat A, Caroppo P, Couratier P, Blanc F, Lacomblez L, Sellal F, et al.: French Clinical and Genetic Research Network on FTLD/FTLD-ALS. TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol Aging 36(11): 3116.e5&#x2013;3116.e8, 2015.</Citation></Reference><Reference><Citation>Revach O-Y, Liu S and Jenkins RW: Targeting TANK-binding kinase 1 (TBK1) in cancer. Expert Opin Ther Targets 24: 1065&#x2013;1078, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1826929</ArticleId><ArticleId IdType="pubmed">32962465</ArticleId><ArticleId IdType="pmc">7644630</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu C, Sankaran B, Chaton CT, Herr AB, Mishra A, Peng J and Li P: Structural insights into the functions of TBK1 in innate antimicrobial immunity. Structure 21: 1137&#x2013;1148, 2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2013.04.025</ArticleId><ArticleId IdType="pubmed">23746807</ArticleId><ArticleId IdType="pmc">3702631</ArticleId></ArticleIdList></Reference><Reference><Citation>Larabi A, Devos Juliette M, Ng S-L, Nanao Max H, Round A, Maniatis T and Panne D: Crystal Structure and Mechanism of Activation of TANK-Binding Kinase 1. Cell Reports 3: 734&#x2013;746, 2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.01.034</ArticleId><ArticleId IdType="pubmed">23453971</ArticleId></ArticleIdList></Reference><Reference><Citation>Larabi A, Devos JM, Ng SL, Nanao MH, Round A, Maniatis T and Panne D: Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep 3: 734&#x2013;746, 2013.</Citation></Reference><Reference><Citation>Borghero G, Pugliatti M, Marrosu F, Marrosu MG, Murru MR, Floris G, Cannas A, Occhineri P, Cau TB, et al.: TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging 43: 180.e181&#x2013;180.e185, 2016.</Citation></Reference><Reference><Citation>Ahmad L, Zhang SY, Casanova JL and Sancho-Shimizu V: Human TBK1: A Gatekeeper of Neuroinflammation. Trends Mol Med 22: 511&#x2013;527, 2016.</Citation></Reference><Reference><Citation>Kawase K, Allingham RR, Meguro A, Mizuki N, Roos B, Solivan-Timpe F, Robin A, Ritch R and Fingert J: Confirmation of TBK1 duplication in normal tension glaucoma. Experimental eye research 96: 178&#x2013;180, 2012.</Citation></Reference><Reference><Citation>van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B, B&#xe4;umer V, Engelborghs S, De Bleecker J, et al.: TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Hum Mutat 38: 297&#x2013;309, 2017.</Citation></Reference><Reference><Citation>Pozzi L, Valenza F, Mosca L, Dal Mas A, Domi T, Romano A, Tarlarini C, Falzone YM, Tremolizzo L, et al.: TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. J Neurol Neurosurg Psychiatry 88: 869&#x2013;875, 2017.</Citation></Reference><Reference><Citation>Swift IJ, Bocchetta M, Benotmane H, Woollacott IO, Shafei R and Rohrer JD: Variable clinical phenotype in TBK1 mutations: case report of a novel mutation causing primary progressive aphasia and review of the literature. Neurobiol Aging 99: 100.e109&#x2013;100.e115, 2021.</Citation></Reference><Reference><Citation>Thanasis Mitsis LP, Aspasia Efthimiadou, Flora Bacopoulou, Dimitrios Vlachakis, George P Chrousos, Elias Eliopoulos: A comprehensive structural and functional analysis of the ligand binding domain of the nuclear receptor superfamily reveals highly conserved signaling motifs and two distinct canonical forms through evolution. World Academy of Sciences Journal 1: 264&#x2013;274, 2019/11/1.</Citation></Reference><Reference><Citation>B Spyropoulos EO, A Danelakis, K Karaboulas, E Kotsiliti, E Maridaki, L Papageorgiou, E Papalexis, C Sakellarios, D Zogogianni, M Botsivaly: A web-based System supporting the Certification of the Outpatient and Emergency Departments and providing for post-discharge Continuity of medical Care Software. 2011.</Citation></Reference><Reference><Citation>Louis Papageorgiou VM, Dimitrios Vlachakis: Genetic and structural study of DNA-directed RNA polymerase II of Trypanosoma brucei, towards the designing of novel antiparasitic agents. PeerJ 5: e3061, 2017/3/1.</Citation></Reference><Reference><Citation>Vassiliki Lila Koumandou LP, Eleni Picasi, Dimitra Mantzouni, Sofia Raftopoulou, Michael Ramm, Aegli Papathanassopoulou, Marianna Hagidimitriou, Nikos Cosmidis, Dimitrios Vlachakis: Genomic analysis of the endosymbiotic bacterium Candidatus Erwinia dacicola provides insights for the management of the olive pest Bactrocera oleae. Journal of Biotechnology 280: S13, 2018/8/30.</Citation></Reference><Reference><Citation>Constantinos Salis LP, E Papakonstantinou, Mariana Hagidimitriou, Dimitrios Vlachakis: Olive Oil Polyphenols in Neurodegenerative Pathologies. Advances in Experimental Medicine and Biology 1195: 77&#x2013;91, 2020/5/29.</Citation></Reference><Reference><Citation>Louis P, Dimitrios V, Vassiliki Lila K, Nikitas P and Sophia K: Computer-Aided Drug Design and Biological Evaluation of Novel Anti-Greek Goat Encephalitis Agents. International Journal of Systems Biology and Biomedical Technologies (IJSBBT) 2: 1&#x2013;16, 2013.</Citation></Reference><Reference><Citation>Waterhouse AM, Procter JB, Martin DMA, Clamp M and Barton GJ: Jalview Version 2&#x2014;a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189&#x2013;1191, 2009.</Citation></Reference><Reference><Citation>Papageorgiou L, Papakonstantinou E, Salis C, Raftopoulou S, Mitsis T, Nicolaides N, Eliopoulos E, Charmandari E, Chrousos G, et al.: An Updated Evolutionary Study in Glucocorticoid Receptors; Insights from a Comprehensive Phylogenetic, SNP&#x2019;s and Mutation&#x2019;s Analysis of the Nuclear Receptors Family: An Updated Evolutionary Study in Glucocorticoid Receptors; Insights from a Comprehensive Phylogenetic, SNP&#x2019;s and Mutation&#x2019;s Analysis of the Nuclear Receptors Family. 2018.</Citation></Reference><Reference><Citation>Dimitrios Vlachakis LP, Vasileios Megalooikonomou: Genetic and Geo-Epidemiological Analysis of the Zika Virus Pandemic; Learning Lessons from the Recent Ebola Outbreak. IntechOpen, 2017.</Citation></Reference><Reference><Citation>Kumar S, Stecher G, Li M, Knyaz C and Tamura K: MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol 35: 1547&#x2013;1549, 2018.</Citation></Reference><Reference><Citation>Robert F and Pelletier J: Exploring the Impact of Single-Nucleotide Polymorphisms on Translation. Frontiers in Genetics 9: 507, 2018.</Citation></Reference><Reference><Citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The Protein Data Bank. Nucleic Acids Research 28: 235&#x2013;242, 2000.</Citation></Reference><Reference><Citation>The UniProt C: UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Research 49: D480&#x2013;D489, 2021.</Citation></Reference><Reference><Citation>MacArthur J, Bowler E, Cerezo M, Gil L, Hall P, Hastings E, Junkins H, McMahon A, Milano A, et al.: The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic acids research 45: D896&#x2013;D901, 2017.</Citation></Reference><Reference><Citation>Zhang C, Shang G, Gui X, Zhang X, Bai XC and Chen ZJ: Structural basis of STING binding with and phosphorylation by TBK1. Nature 567: 394&#x2013;398, 2019.</Citation></Reference><Reference><Citation>Louis Papageorgiou SL, Kossida Sofia, Dimitrios Maroulis, Dimitrios Vlachakis: An updated evolutionary study of Flaviviridae NS3 helicase and NS5 RNA-dependent RNA polymerase reveals novel invariable motifs as potential pharmacological targets. Molecular BioSystems 12: 2016.</Citation></Reference><Reference><Citation>Louis Papageorgiou SL, Vassiliki Lila Koumandou, Wojciech Maka&#x142;owski, Vasileios Megalooikonomou, Dimitrios Vlachakis, Sophia Kossida: Structural models for the design of novel antiviral agents against Greek Goat Encephalitis. PeerJ e664, 2014.</Citation></Reference><Reference><Citation>Dimitrios Vlachakis SCT, Katerina Ioannidou, Louis Papageorgiou, Marc Baumann, Sophia Kossida: A series of Notch3 mutations in CADASIL; insights from 3D molecular modelling and evolutionary analyses. Journal of molecular biochemistry 3: 2014.</Citation></Reference><Reference><Citation>Konno H, Yamauchi S, Berglund A, Putney RM, Mule JJ and Barber GN: Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37: 2037&#x2013;2051, 2018.</Citation></Reference><Reference><Citation>Dimitrios Vlachakis EIZ, Eirini Tsiamaki, Maria Koulouri, Sofia Raftopoulou, Louis Papageorgiou, George P Chrousos, John Ellul, Vasileios Megalooikonomou: Insights into the molecular mechanisms of stress and inflammation in ageing and frailty of the elderly molecular biochemistry. Journal of molecular biochemistry 6: 41, 2017.</Citation></Reference><Reference><Citation>de Majo M, Topp SD, Smith BN, Nishimura AL, Chen HJ, Gkazi AS, Miller J, Wong CH, Vance C, et al.: ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol Aging 71: 266.e261&#x2013;266.e210, 2018.</Citation></Reference><Reference><Citation>Lattante S, Doronzio PN, Marangi G, Conte A, Bisogni G, Bernardo D, Russo T, Lamberti D, Patrizi S, et al.: Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiology of Aging 84: 239.e239&#x2013;239.e214, 2019.</Citation></Reference><Reference><Citation>Ye J, Cheung J, Gerbino V, Ahls&#xe9;n G, Zimanyi C, Hirsh D and Maniatis T: Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity. Proc Natl Acad Sci U S A 116: 24517&#x2013;24526, 2019.</Citation></Reference><Reference><Citation>Wu S, Zhang Q, Zhang F, Meng F, Liu S, Ruyuan Z, Wu Q, Li X, Shen L, et al.: HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nature Cell Biology 2019.</Citation></Reference><Reference><Citation>Weber TJ: 2.24 &#x2013; Protein Kinases. In: Comprehensive Toxicology (Second Edition). McQueen CA (ed). Elsevier, Oxford, pp 473&#x2013;493, 2010.</Citation></Reference><Reference><Citation>TD B: Introduction to Enzyme and Coenzyme Chemistry (PDF) (2nd ed.). Blackwell Publishing Limited. ISBN 9781405114523. Archived from the original (PDF) on 22 March 2018. Blackwell Publishing Limited ISBN 9781405114523 Archived from the original (PDF) on 22 March 2018 (2004).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>